U.S. market Closed. Opens in 17 hours 14 minutes

VCNX | Vaccinex, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 5.50 - 5.75
52 Week Range 4.21 - 52.50
Beta 0.10
Implied Volatility 566.87%
IV Rank 20.19%
Day's Volume 7,865
Average Volume 79,098
Shares Outstanding 1,727,700
Market Cap 9,899,721
Sector Healthcare
Industry Biotechnology
IPO Date 2018-08-09
Valuation
Profitability
Growth
Health
P/E Ratio -1.45
Forward P/E Ratio N/A
EPS -3.96
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 37
Country USA
Website VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
*Chart delayed
Analyzing fundamentals for VCNX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very wealthy, Growth is bad and Health is frighteningly weak. For more detailed analysis please see VCNX Fundamentals page.

Watching at VCNX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on VCNX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙